Short answer
Cartesian Therapeutics, Inc. (RNAC) filed its Q1 2026 10-Q quarterly report on Apr 30, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $0 (down 100.0% year over year) with net income of −$39M.
Q1 2026 key financials · XBRL
- Revenue
- $0
- −100.0% YoY
- Net income
- −$39M
- −121.2% YoY
- EPS (diluted)
- −$1.46
- −114.7% YoY
Source: XBRL data from the Cartesian Therapeutics, Inc. (RNAC) Q1 2026 10-Q on SEC EDGAR. USD.
Cartesian Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $78 thousand, down 93% YoY from $1.1 million
- Net loss $39.2 million vs $17.7 million YoY, with operating loss $26.5 million vs $21.9 million
- Descartes-08 MG R&D $12.1 million, up 72% YoY, best-performing program
- Cash, cash equivalents and restricted cash $120.4 million at March 31, 2026
- Operating cash use $22.1 million; $15.7 million financing inflow from equity sales
- Funding runway at least 12 months, but additional capital needed amid continuing losses and clinical-development costs
Risk Factors
- Risk Factors section not provided in the submitted text
- No new, updated, regulatory, operational, competitive, market, or financial risks identifiable
- Submitted content covers Items 2–6, exhibits, and signatures only
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Cartesian Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.